224 results
ARS
2023 FY
MYGN
Myriad Genetics, Inc.
17 Apr 24
Annual report to shareholders
4:33pm
. Laboratories in the United States that perform testing on human specimens for the purpose of providing information for the diagnosis, prevention … the safety and efficacy of the IVD for its intended purpose. If the device is determined to present a “significant risk,” the sponsor may not begin a clinical
8-K
EX-1.1
6t0f7y4xvz
13 Nov 23
Entry into a Material Definitive Agreement
4:31pm
424B5
2ldrnq6w47oxrda35
13 Nov 23
Prospectus supplement for primary offering
6:02am
424B5
trviqsc cx1f
8 Nov 23
Prospectus supplement for primary offering
4:05pm
S-3ASR
xc57v1 7xoazmoh959e
8 Nov 23
Automatic shelf registration
4:01pm
S-3ASR
EX-4.3
herc46k fr71lu7cns
8 Nov 23
Automatic shelf registration
4:01pm
8-K
EX-10.1
dkfl8po2j8p
31 Oct 23
Entry into a Material Definitive Agreement
4:34pm
8-K
EX-10.1
50b2m40vkna085
5 Oct 23
Departure of Directors or Certain Officers
8:30am
8-K
EX-10.2
4m63068699z7o
6 Jul 23
Entry into a Material Definitive Agreement
8:24am
8-K
EX-10.1
rklehkhocjhaea6t xon
6 Jul 23
Entry into a Material Definitive Agreement
8:24am